Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen(City Of Hope National Medical Center), Ajay K. Gopal(University of Washington), Scott E. Smith(Loyola University Medical Center), Stephen M. Ansell(Mayo Clinic in Arizona), Joseph D. Rosenblatt(University of Miami), Kerry J. Savage(BC Cancer Agency), Joseph M. Connors(BC Cancer Agency), Andreas Engert(University Hospital Cologne), Emily K. Larsen(Seagen (United States)), Dirk Huebner, Abraham Fong(Seagen (United States)), Anas Younes(Memorial Sloan Kettering Cancer Center)
Cited by 393Open Access
Abstract
Key Points A total of 38% of patients who achieved CR (13 of 34) on brentuximab vedotin have remained in remission for >5 years and may be cured. Nine of the 13 patients (9% of all enrolled patients) have remained in long-term remission without a consolidative allogeneic transplant.
Related Papers
No related papers found
Powered by citation graph analysis